Sanofi secures two breakthrough nods in China for rare blood disorders

Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia

Merck KGaA’s Cladribine capsules gain FDA fast track for rare neuromuscular disorder

FDA investigates fatal case linked to rare blood disorder drug Adzynma

Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme

Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders

Contera Pharma will receive an upfront payment and full research funding for each target under investigation

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada

Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders

Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders

In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers